Recent studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing significant outcomes in treating excess mass and type 2 condition. Animal data suggest a distinct mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/